导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.73% | 2728/4773 |
| 近一周 | -2.17% | 1379/5462 |
| 近一月 | -4.07% | 2191/5421 |
| 近一季 | -7.23% | 2340/5209 |
| 近半年 | -2.55% | 1948/4920 |
| 近一年 | 0.57% | 2536/4366 |
| 近两年 | 43.16% | 1728/2954 |
| 近三年 | 26.46% | 1207/2253 |
| 成立以来 | 15.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.64% 3329/4961 |
12.06% 2241/5312 |
- - |
- - |
| 2025 | 19.15% 2246/4813 |
-1.02% 2537/3635 |
2.13% 1830/4076 |
17.80% 2435/4524 |
0.05% 2255/4813 |
| 2024 | 15.81% 880/3463 |
3.00% 637/2808 |
-1.02% 894/3014 |
15.74% 1635/3129 |
-1.86% 1865/3463 |
| 2023 | -9.30% 1147/2656 |
4.18% 1029/2280 |
-3.90% 960/2385 |
-3.31% 891/2515 |
-6.30% 1711/2655 |
| 2022 | -19.86% 909/2207 |
-14.41% 943/1919 |
6.73% 618/2016 |
-13.62% 934/2113 |
1.55% 1224/2208 |
| 2021 | -3.67% 924/1822 |
-3.20% 778/1255 |
4.25% 908/1330 |
-5.79% 860/1466 |
1.33% 962/1822 |
| 2020 | - - |
- - |
- - |
5.06% 931/1164 |
12.80% 432/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 泰康沪深300ETF联接A VS. 长安沪深300非周期A(740101) |